| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Thyroidectomy | 6 | 2021 | 207 | 2.28 | Why? |
| Rectal Neoplasms | 9 | 2018 | 278 | 2.16 | Why? |
| Colectomy | 6 | 2018 | 327 | 1.89 | Why? |
| Colonic Neoplasms | 5 | 2018 | 295 | 1.82 | Why? |
| Thyroid Neoplasms | 5 | 2021 | 422 | 1.67 | Why? |
| Laparoscopy | 5 | 2018 | 1532 | 1.04 | Why? |
| Adenocarcinoma | 4 | 2018 | 651 | 1.01 | Why? |
| Vocal Cord Dysfunction | 1 | 2020 | 4 | 0.89 | Why? |
| Neoadjuvant Therapy | 5 | 2018 | 554 | 0.86 | Why? |
| Hypocalcemia | 2 | 2019 | 120 | 0.85 | Why? |
| Thyroid Gland | 3 | 2021 | 516 | 0.84 | Why? |
| Recurrent Laryngeal Nerve Injuries | 2 | 2020 | 34 | 0.81 | Why? |
| Lithium Chloride | 1 | 2018 | 14 | 0.77 | Why? |
| Neoplasm Staging | 6 | 2020 | 1999 | 0.76 | Why? |
| Intraoperative Complications | 2 | 2018 | 221 | 0.75 | Why? |
| Intraoperative Neurophysiological Monitoring | 1 | 2018 | 30 | 0.75 | Why? |
| Colon, Transverse | 1 | 2018 | 9 | 0.74 | Why? |
| Genomic Instability | 1 | 2018 | 80 | 0.73 | Why? |
| Gastrectomy | 2 | 2017 | 225 | 0.72 | Why? |
| Rosaniline Dyes | 1 | 2017 | 18 | 0.72 | Why? |
| Lymphoscintigraphy | 1 | 2017 | 18 | 0.72 | Why? |
| Video-Assisted Surgery | 1 | 2018 | 43 | 0.72 | Why? |
| Postoperative Complications | 6 | 2020 | 5861 | 0.72 | Why? |
| Adenocarcinoma, Follicular | 1 | 2017 | 21 | 0.71 | Why? |
| Capecitabine | 1 | 2017 | 51 | 0.71 | Why? |
| Sentinel Lymph Node | 1 | 2017 | 35 | 0.68 | Why? |
| Valproic Acid | 1 | 2017 | 114 | 0.65 | Why? |
| Carcinoma, Papillary | 1 | 2017 | 76 | 0.65 | Why? |
| Colorectal Neoplasms | 4 | 2018 | 1884 | 0.64 | Why? |
| Conversion to Open Surgery | 1 | 2016 | 35 | 0.63 | Why? |
| Thyroid Nodule | 1 | 2017 | 70 | 0.63 | Why? |
| Diverticulitis, Colonic | 1 | 2016 | 38 | 0.61 | Why? |
| Epithelial-Mesenchymal Transition | 1 | 2018 | 242 | 0.61 | Why? |
| Tumor Suppressor Protein p53 | 1 | 2017 | 310 | 0.58 | Why? |
| Digestive System Surgical Procedures | 3 | 2020 | 677 | 0.58 | Why? |
| Interleukin-10 Receptor alpha Subunit | 1 | 2013 | 1 | 0.56 | Why? |
| Receptors, CXCR | 1 | 2014 | 8 | 0.56 | Why? |
| Interleukin-10 Receptor beta Subunit | 1 | 2013 | 111 | 0.53 | Why? |
| Receptors, CXCR4 | 1 | 2014 | 83 | 0.53 | Why? |
| Surgical Oncology | 2 | 2021 | 923 | 0.53 | Why? |
| Delphi Technique | 1 | 2018 | 1257 | 0.51 | Why? |
| Quality Assurance, Health Care | 1 | 2018 | 596 | 0.49 | Why? |
| Lymph Nodes | 1 | 2018 | 1060 | 0.44 | Why? |
| Stomach Neoplasms | 1 | 2017 | 477 | 0.44 | Why? |
| Point Mutation | 1 | 2013 | 481 | 0.42 | Why? |
| Positron Emission Tomography Computed Tomography | 2 | 2017 | 1458 | 0.40 | Why? |
| Fluorodeoxyglucose F18 | 2 | 2017 | 1153 | 0.40 | Why? |
| Coloring Agents | 2 | 2017 | 116 | 0.40 | Why? |
| Anastomosis, Surgical | 3 | 2018 | 169 | 0.37 | Why? |
| Operative Time | 3 | 2020 | 450 | 0.35 | Why? |
| Polymorphism, Genetic | 1 | 2013 | 1074 | 0.31 | Why? |
| Elective Surgical Procedures | 2 | 2020 | 5338 | 0.30 | Why? |
| Colitis, Ulcerative | 1 | 2013 | 1037 | 0.27 | Why? |
| Tattooing | 1 | 2003 | 27 | 0.26 | Why? |
| Lymphatic Diseases | 1 | 2003 | 96 | 0.24 | Why? |
| Vocal Cord Paralysis | 2 | 2020 | 51 | 0.24 | Why? |
| Rectum | 3 | 2020 | 495 | 0.23 | Why? |
| Colon | 2 | 2020 | 669 | 0.23 | Why? |
| Societies, Medical | 1 | 2018 | 6907 | 0.22 | Why? |
| Surgery Department, Hospital | 2 | 2020 | 954 | 0.21 | Why? |
| Ovarian Neoplasms | 2 | 2017 | 465 | 0.21 | Why? |
| Chemoradiotherapy, Adjuvant | 2 | 2018 | 69 | 0.21 | Why? |
| Prognosis | 9 | 2018 | 32490 | 0.21 | Why? |
| ROC Curve | 4 | 2017 | 6024 | 0.21 | Why? |
| Italy | 13 | 2021 | 38444 | 0.20 | Why? |
| Glycogen Synthase Kinase 3 beta | 1 | 2018 | 45 | 0.19 | Why? |
| Cell Plasticity | 1 | 2018 | 75 | 0.19 | Why? |
| Preoperative Care | 3 | 2017 | 1515 | 0.18 | Why? |
| Neoplasm Metastasis | 2 | 2018 | 682 | 0.18 | Why? |
| Spheroids, Cellular | 1 | 2018 | 124 | 0.18 | Why? |
| Inflammatory Bowel Diseases | 1 | 2016 | 3209 | 0.18 | Why? |
| Magnetic Resonance Imaging | 4 | 2018 | 6551 | 0.18 | Why? |
| Cell Adhesion | 1 | 2018 | 230 | 0.17 | Why? |
| Parathyroid Neoplasms | 1 | 2017 | 18 | 0.17 | Why? |
| Surgical Stapling | 1 | 2017 | 19 | 0.17 | Why? |
| Kaplan-Meier Estimate | 3 | 2018 | 4260 | 0.17 | Why? |
| Hernia, Diaphragmatic, Traumatic | 1 | 2016 | 1 | 0.17 | Why? |
| Parathyroidectomy | 1 | 2017 | 32 | 0.17 | Why? |
| Anastomotic Leak | 1 | 2017 | 46 | 0.17 | Why? |
| Ultrasonic Surgical Procedures | 1 | 2016 | 11 | 0.17 | Why? |
| Abdominal Pain | 1 | 2003 | 858 | 0.17 | Why? |
| Biomarkers, Tumor | 2 | 2018 | 1314 | 0.17 | Why? |
| Image Enhancement | 1 | 2018 | 177 | 0.16 | Why? |
| Colonoscopy | 1 | 2003 | 738 | 0.16 | Why? |
| Medical Audit | 1 | 2018 | 218 | 0.16 | Why? |
| Aged | 19 | 2020 | 215776 | 0.16 | Why? |
| Ovariectomy | 1 | 2016 | 53 | 0.16 | Why? |
| Cytoreduction Surgical Procedures | 1 | 2017 | 144 | 0.16 | Why? |
| Peritoneal Neoplasms | 1 | 2017 | 110 | 0.16 | Why? |
| Thyroid Diseases | 1 | 2020 | 285 | 0.16 | Why? |
| Minimally Invasive Surgical Procedures | 1 | 2021 | 663 | 0.15 | Why? |
| Follow-Up Studies | 4 | 2018 | 17020 | 0.15 | Why? |
| Hyperthermia, Induced | 1 | 2017 | 106 | 0.15 | Why? |
| Radionuclide Imaging | 1 | 2017 | 184 | 0.15 | Why? |
| Chemoradiotherapy | 2 | 2018 | 362 | 0.15 | Why? |
| Diffusion Magnetic Resonance Imaging | 1 | 2017 | 317 | 0.15 | Why? |
| Middle Aged | 20 | 2020 | 270681 | 0.15 | Why? |
| Injections, Subcutaneous | 1 | 2017 | 647 | 0.15 | Why? |
| Tumor Burden | 1 | 2017 | 369 | 0.15 | Why? |
| Humans | 40 | 2021 | 930598 | 0.14 | Why? |
| Neoplasms | 3 | 2021 | 17251 | 0.14 | Why? |
| Radiopharmaceuticals | 2 | 2017 | 763 | 0.14 | Why? |
| Contrast Media | 2 | 2018 | 1011 | 0.14 | Why? |
| Hamartoma Syndrome, Multiple | 1 | 2013 | 4 | 0.14 | Why? |
| Retrospective Studies | 11 | 2021 | 105322 | 0.14 | Why? |
| Adenomatous Polyposis Coli | 1 | 2013 | 11 | 0.14 | Why? |
| Cell Movement | 1 | 2018 | 695 | 0.14 | Why? |
| Radiation Tolerance | 1 | 2014 | 25 | 0.14 | Why? |
| Neoplasm Invasiveness | 1 | 2017 | 582 | 0.14 | Why? |
| Heredity | 1 | 2013 | 37 | 0.14 | Why? |
| Adenoma | 1 | 2017 | 215 | 0.14 | Why? |
| Lymphatic Metastasis | 1 | 2017 | 537 | 0.14 | Why? |
| Lymph Node Excision | 1 | 2017 | 362 | 0.14 | Why? |
| Chemokine CXCL12 | 1 | 2014 | 74 | 0.14 | Why? |
| Female | 23 | 2020 | 380317 | 0.13 | Why? |
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2013 | 55 | 0.13 | Why? |
| Calcium | 1 | 2019 | 708 | 0.13 | Why? |
| beta Catenin | 1 | 2013 | 78 | 0.13 | Why? |
| Mesalamine | 1 | 2013 | 89 | 0.13 | Why? |
| Diaphragm | 1 | 2016 | 232 | 0.13 | Why? |
| Hospital Administration | 1 | 2020 | 650 | 0.13 | Why? |
| Male | 19 | 2020 | 367725 | 0.13 | Why? |
| Azathioprine | 1 | 2013 | 161 | 0.12 | Why? |
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2013 | 229 | 0.12 | Why? |
| Practice Guidelines as Topic | 1 | 2017 | 15421 | 0.12 | Why? |
| Pedigree | 1 | 2013 | 502 | 0.12 | Why? |
| Gynecologic Surgical Procedures | 1 | 2017 | 489 | 0.12 | Why? |
| Hospitals, Teaching | 1 | 2020 | 1609 | 0.12 | Why? |
| Age of Onset | 1 | 2013 | 557 | 0.11 | Why? |
| Radiotherapy | 1 | 2017 | 608 | 0.11 | Why? |
| Combined Modality Therapy | 2 | 2017 | 3395 | 0.11 | Why? |
| Aged, 80 and over | 8 | 2019 | 88759 | 0.10 | Why? |
| Chronic Pain | 1 | 2019 | 736 | 0.10 | Why? |
| Area Under Curve | 2 | 2017 | 2564 | 0.10 | Why? |
| Drug Resistance, Neoplasm | 1 | 2014 | 447 | 0.10 | Why? |
| Bariatric Surgery | 1 | 2021 | 1298 | 0.10 | Why? |
| Promoter Regions, Genetic | 1 | 2013 | 823 | 0.10 | Why? |
| Obesity, Morbid | 1 | 2021 | 1340 | 0.10 | Why? |
| Cell Line, Tumor | 1 | 2018 | 3608 | 0.10 | Why? |
| Fibroblasts | 1 | 2013 | 839 | 0.10 | Why? |
| Incidence | 4 | 2021 | 25622 | 0.10 | Why? |
| Gastrointestinal Agents | 1 | 2013 | 393 | 0.10 | Why? |
| Operating Rooms | 1 | 2020 | 1841 | 0.10 | Why? |
| Flow Cytometry | 1 | 2017 | 2393 | 0.09 | Why? |
| Disease-Free Survival | 1 | 2014 | 1654 | 0.09 | Why? |
| Adult | 11 | 2020 | 244371 | 0.09 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.09 | Why? |
| Disease Outbreaks | 3 | 2021 | 27595 | 0.09 | Why? |
| General Surgery | 1 | 2020 | 1472 | 0.09 | Why? |
| Quality Improvement | 1 | 2020 | 2435 | 0.09 | Why? |
| Neoplasm Recurrence, Local | 1 | 2014 | 1063 | 0.08 | Why? |
| Treatment Outcome | 6 | 2018 | 51732 | 0.08 | Why? |
| Immunohistochemistry | 1 | 2014 | 2275 | 0.08 | Why? |
| Fever | 1 | 2003 | 7795 | 0.08 | Why? |
| Intestinal Mucosa | 1 | 2013 | 1046 | 0.07 | Why? |
| Proportional Hazards Models | 2 | 2018 | 6543 | 0.07 | Why? |
| Emergencies | 1 | 2020 | 4095 | 0.07 | Why? |
| Health Services Needs and Demand | 1 | 2020 | 3419 | 0.07 | Why? |
| Early Detection of Cancer | 1 | 2017 | 1956 | 0.07 | Why? |
| Length of Stay | 2 | 2020 | 11042 | 0.07 | Why? |
| Medical Oncology | 1 | 2020 | 3826 | 0.06 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.06 | Why? |
| Tertiary Care Centers | 1 | 2020 | 8248 | 0.06 | Why? |
| Phenotype | 1 | 2013 | 4037 | 0.06 | Why? |
| Cells, Cultured | 1 | 2013 | 5835 | 0.06 | Why? |
| Patient Selection | 1 | 2017 | 4560 | 0.06 | Why? |
| Comorbidity | 4 | 2021 | 34796 | 0.06 | Why? |
| Anti-Infective Agents | 1 | 2013 | 1766 | 0.06 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.06 | Why? |
| Colonic Polyps | 1 | 2003 | 117 | 0.06 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.06 | Why? |
| Ultrasonography | 1 | 2017 | 4409 | 0.05 | Why? |
| Prospective Studies | 4 | 2018 | 43301 | 0.05 | Why? |
| Time Factors | 2 | 2020 | 31397 | 0.05 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.05 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.05 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.05 | Why? |
| Biopsy, Fine-Needle | 1 | 2020 | 274 | 0.05 | Why? |
| Disease Progression | 1 | 2018 | 13580 | 0.05 | Why? |
| RNA, Messenger | 1 | 2013 | 5131 | 0.05 | Why? |
| Genetic Predisposition to Disease | 1 | 2013 | 4027 | 0.05 | Why? |
| Risk Factors | 2 | 2019 | 71621 | 0.05 | Why? |
| Technetium Tc 99m Sestamibi | 1 | 2017 | 20 | 0.04 | Why? |
| Siloxanes | 1 | 2017 | 8 | 0.04 | Why? |
| Predictive Value of Tests | 3 | 2018 | 9537 | 0.04 | Why? |
| Adolescent | 2 | 2019 | 86841 | 0.04 | Why? |
| China | 2 | 2021 | 50654 | 0.04 | Why? |
| Young Adult | 2 | 2019 | 93724 | 0.04 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.04 | Why? |
| Radiotherapy Planning, Computer-Assisted | 1 | 2017 | 172 | 0.04 | Why? |
| Reproducibility of Results | 3 | 2018 | 11304 | 0.04 | Why? |
| Surgical Mesh | 1 | 2016 | 55 | 0.04 | Why? |
| Perfusion | 1 | 2017 | 254 | 0.04 | Why? |
| Regional Blood Flow | 1 | 2017 | 172 | 0.04 | Why? |
| Pulmonary Atelectasis | 1 | 2016 | 80 | 0.04 | Why? |
| Magnetite Nanoparticles | 1 | 2017 | 109 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.04 | Why? |
| Suture Techniques | 1 | 2016 | 138 | 0.04 | Why? |
| Perfusion Imaging | 1 | 2017 | 199 | 0.04 | Why? |
| Analgesics | 1 | 2019 | 451 | 0.04 | Why? |
| Biomarkers | 2 | 2018 | 23361 | 0.03 | Why? |
| Intestinal Obstruction | 1 | 2016 | 197 | 0.03 | Why? |
| Anal Canal | 1 | 2017 | 367 | 0.03 | Why? |
| Remission Induction | 1 | 2017 | 950 | 0.03 | Why? |
| Sensitivity and Specificity | 3 | 2018 | 22971 | 0.03 | Why? |
| Infection Control | 1 | 2021 | 23131 | 0.03 | Why? |
| Risk Assessment | 1 | 2016 | 25439 | 0.03 | Why? |
| Infant | 1 | 2013 | 30274 | 0.03 | Why? |
| Telemedicine | 1 | 2021 | 25032 | 0.02 | Why? |
| Iran | 1 | 2020 | 5467 | 0.02 | Why? |
| Republic of Korea | 1 | 2020 | 5858 | 0.02 | Why? |
| Recovery of Function | 1 | 2017 | 2461 | 0.02 | Why? |
| Hospitals, University | 1 | 2019 | 4173 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.02 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.01 | Why? |
| Registries | 1 | 2019 | 12327 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2020 | 43792 | 0.01 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2016 | 25144 | 0.01 | Why? |